Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
Identifieur interne : 000450 ( PubMed/Corpus ); précédent : 000449; suivant : 000451Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
Auteurs : Christopher R. Chapple ; Jameel Nazir ; Zalmai Hakimi ; Sally Bowditch ; Francis Fatoye ; Florent Guelfucci ; Amine Khemiri ; Emad Siddiqui ; Adrian WaggSource :
- European urology [ 1873-7560 ] ; 2017.
English descriptors
- KwdEn :
- Acetanilides (administration & dosage), Acetanilides (adverse effects), Adrenergic beta-3 Receptor Agonists (administration & dosage), Adrenergic beta-3 Receptor Agonists (adverse effects), Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Chi-Square Distribution (MeSH), Databases, Factual (MeSH), Drug Administration Schedule (MeSH), Female (MeSH), Humans (MeSH), Kaplan-Meier Estimate (MeSH), Logistic Models (MeSH), Longitudinal Studies (MeSH), Male (MeSH), Medication Adherence (MeSH), Middle Aged (MeSH), Muscarinic Antagonists (administration & dosage), Muscarinic Antagonists (adverse effects), Odds Ratio (MeSH), Proportional Hazards Models (MeSH), Retrospective Studies (MeSH), Thiazoles (administration & dosage), Thiazoles (adverse effects), Time Factors (MeSH), Treatment Outcome (MeSH), United Kingdom (MeSH), Urinary Bladder, Overactive (diagnosis), Urinary Bladder, Overactive (drug therapy), Urinary Bladder, Overactive (physiopathology), Urological Agents (administration & dosage), Urological Agents (adverse effects), Young Adult (MeSH).
- MESH :
- chemical , administration & dosage : Acetanilides, Adrenergic beta-3 Receptor Agonists, Muscarinic Antagonists, Thiazoles, Urological Agents.
- chemical , adverse effects : Acetanilides, Adrenergic beta-3 Receptor Agonists, Muscarinic Antagonists, Thiazoles, Urological Agents.
- diagnosis : Urinary Bladder, Overactive.
- drug therapy : Urinary Bladder, Overactive.
- physiopathology : Urinary Bladder, Overactive.
- Adult, Aged, Aged, 80 and over, Chi-Square Distribution, Databases, Factual, Drug Administration Schedule, Female, Humans, Kaplan-Meier Estimate, Logistic Models, Longitudinal Studies, Male, Medication Adherence, Middle Aged, Odds Ratio, Proportional Hazards Models, Retrospective Studies, Time Factors, Treatment Outcome, United Kingdom, Young Adult.
Abstract
BACKGROUND
Persistence with antimuscarinic therapy in overactive bladder (OAB) is poor, but may be different for mirabegron, a β
OBJECTIVE
To compare persistence and adherence with mirabegron versus tolterodine extended release (ER) and other antimuscarinics in routine clinical practice over a 12-mo period.
DESIGN, SETTING, AND PARTICIPANTS
Retrospective, longitudinal, observational study of anonymised data from the UK Clinical Practice Research Datalink GOLD database. Eligibility: age ≥18 yr, ≥1 prescription for target OAB drug (between May 1, 2013 and June 29, 2014), and 12-mo continuous enrolment before and after the index prescription date.
INTERVENTIONS
Mirabegron, darifenacin, fesoterodine, flavoxate, oxybutynin ER or immediate-release (IR), propiverine, solifenacin, tolterodine ER or IR, and trospium chloride.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS
The primary endpoint was persistence (time to discontinuation). Secondary endpoints included 12-mo persistence rates and adherence (assessed using medication possession ratio, MPR). Cox proportional-hazards regression models and logistic regression models adjusted for potential confounding factors were used to compare cohorts. Analyses were repeated after 1:1 matching.
RESULTS AND LIMITATIONS
The study population included 21996 eligible patients. In the unmatched analysis, the median time-to-discontinuation was significantly longer for mirabegron (169 d, interquartile range [IQR] 41-not reached) compared to tolterodine ER (56 d, IQR 28-254; adjusted hazard ratio [HR] 1.55, 95% confidence interval 1.41-1.71; p<0.0001) and other antimuscarinics (range 30-78 d; adjusted HR range 1.24-2.26, p<0.0001 for all comparisons). The 12-mo persistence rates and MPR were also significantly greater with mirabegron than with all the antimuscarinics. Limitations include the retrospective design, use of prescription records to estimate outcomes, and inability to capture reasons for discontinuation.
CONCLUSIONS
Persistence and adherence were statistically significantly greater with mirabegron than with tolterodine ER and other antimuscarinics prescribed for OAB in the UK.
PATIENT SUMMARY
This study assessed persistence and adherence (or compliance) with medications prescribed for OAB in a large UK population. We found that patients prescribed mirabegron remained on treatment for longer and showed greater adherence than those prescribed traditional antimuscarinics.
DOI: 10.1016/j.eururo.2017.01.037
PubMed: 28196724
Links to Exploration step
pubmed:28196724Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.</title><author><name sortKey="Chapple, Christopher R" sort="Chapple, Christopher R" uniqKey="Chapple C" first="Christopher R" last="Chapple">Christopher R. Chapple</name><affiliation><nlm:affiliation>Department of Urology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals, Sheffield, UK. Electronic address: c.r.chapple@sheffield.ac.uk.</nlm:affiliation></affiliation></author><author><name sortKey="Nazir, Jameel" sort="Nazir, Jameel" uniqKey="Nazir J" first="Jameel" last="Nazir">Jameel Nazir</name><affiliation><nlm:affiliation>Astellas Pharma Europe Ltd., Astellas Medical Affairs, EMEA, HEOR, Chertsey, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Hakimi, Zalmai" sort="Hakimi, Zalmai" uniqKey="Hakimi Z" first="Zalmai" last="Hakimi">Zalmai Hakimi</name><affiliation><nlm:affiliation>Astellas Pharma Europe B.V., Astellas Medical Affairs, Global, HEOR, Leiden, Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Bowditch, Sally" sort="Bowditch, Sally" uniqKey="Bowditch S" first="Sally" last="Bowditch">Sally Bowditch</name><affiliation><nlm:affiliation>Astellas Pharma Europe Ltd., Astellas Medical Affairs, EMEA, HEOR, Chertsey, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Fatoye, Francis" sort="Fatoye, Francis" uniqKey="Fatoye F" first="Francis" last="Fatoye">Francis Fatoye</name><affiliation><nlm:affiliation>Department of Health Professions, Manchester Metropolitan University, Manchester, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Guelfucci, Florent" sort="Guelfucci, Florent" uniqKey="Guelfucci F" first="Florent" last="Guelfucci">Florent Guelfucci</name><affiliation><nlm:affiliation>Creativ-Ceutical, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Khemiri, Amine" sort="Khemiri, Amine" uniqKey="Khemiri A" first="Amine" last="Khemiri">Amine Khemiri</name><affiliation><nlm:affiliation>Creativ-Ceutical SARL, Les Berges du lac, Tunisia.</nlm:affiliation></affiliation></author><author><name sortKey="Siddiqui, Emad" sort="Siddiqui, Emad" uniqKey="Siddiqui E" first="Emad" last="Siddiqui">Emad Siddiqui</name><affiliation><nlm:affiliation>Astellas Pharma Europe Ltd., Astellas Medical Affairs, EMEA, HEOR, Chertsey, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Wagg, Adrian" sort="Wagg, Adrian" uniqKey="Wagg A" first="Adrian" last="Wagg">Adrian Wagg</name><affiliation><nlm:affiliation>Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28196724</idno><idno type="pmid">28196724</idno><idno type="doi">10.1016/j.eururo.2017.01.037</idno><idno type="wicri:Area/PubMed/Corpus">000450</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000450</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.</title><author><name sortKey="Chapple, Christopher R" sort="Chapple, Christopher R" uniqKey="Chapple C" first="Christopher R" last="Chapple">Christopher R. Chapple</name><affiliation><nlm:affiliation>Department of Urology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals, Sheffield, UK. Electronic address: c.r.chapple@sheffield.ac.uk.</nlm:affiliation></affiliation></author><author><name sortKey="Nazir, Jameel" sort="Nazir, Jameel" uniqKey="Nazir J" first="Jameel" last="Nazir">Jameel Nazir</name><affiliation><nlm:affiliation>Astellas Pharma Europe Ltd., Astellas Medical Affairs, EMEA, HEOR, Chertsey, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Hakimi, Zalmai" sort="Hakimi, Zalmai" uniqKey="Hakimi Z" first="Zalmai" last="Hakimi">Zalmai Hakimi</name><affiliation><nlm:affiliation>Astellas Pharma Europe B.V., Astellas Medical Affairs, Global, HEOR, Leiden, Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Bowditch, Sally" sort="Bowditch, Sally" uniqKey="Bowditch S" first="Sally" last="Bowditch">Sally Bowditch</name><affiliation><nlm:affiliation>Astellas Pharma Europe Ltd., Astellas Medical Affairs, EMEA, HEOR, Chertsey, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Fatoye, Francis" sort="Fatoye, Francis" uniqKey="Fatoye F" first="Francis" last="Fatoye">Francis Fatoye</name><affiliation><nlm:affiliation>Department of Health Professions, Manchester Metropolitan University, Manchester, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Guelfucci, Florent" sort="Guelfucci, Florent" uniqKey="Guelfucci F" first="Florent" last="Guelfucci">Florent Guelfucci</name><affiliation><nlm:affiliation>Creativ-Ceutical, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Khemiri, Amine" sort="Khemiri, Amine" uniqKey="Khemiri A" first="Amine" last="Khemiri">Amine Khemiri</name><affiliation><nlm:affiliation>Creativ-Ceutical SARL, Les Berges du lac, Tunisia.</nlm:affiliation></affiliation></author><author><name sortKey="Siddiqui, Emad" sort="Siddiqui, Emad" uniqKey="Siddiqui E" first="Emad" last="Siddiqui">Emad Siddiqui</name><affiliation><nlm:affiliation>Astellas Pharma Europe Ltd., Astellas Medical Affairs, EMEA, HEOR, Chertsey, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Wagg, Adrian" sort="Wagg, Adrian" uniqKey="Wagg A" first="Adrian" last="Wagg">Adrian Wagg</name><affiliation><nlm:affiliation>Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.</nlm:affiliation></affiliation></author></analytic><series><title level="j">European urology</title><idno type="eISSN">1873-7560</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetanilides (administration & dosage)</term><term>Acetanilides (adverse effects)</term><term>Adrenergic beta-3 Receptor Agonists (administration & dosage)</term><term>Adrenergic beta-3 Receptor Agonists (adverse effects)</term><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Chi-Square Distribution (MeSH)</term><term>Databases, Factual (MeSH)</term><term>Drug Administration Schedule (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Kaplan-Meier Estimate (MeSH)</term><term>Logistic Models (MeSH)</term><term>Longitudinal Studies (MeSH)</term><term>Male (MeSH)</term><term>Medication Adherence (MeSH)</term><term>Middle Aged (MeSH)</term><term>Muscarinic Antagonists (administration & dosage)</term><term>Muscarinic Antagonists (adverse effects)</term><term>Odds Ratio (MeSH)</term><term>Proportional Hazards Models (MeSH)</term><term>Retrospective Studies (MeSH)</term><term>Thiazoles (administration & dosage)</term><term>Thiazoles (adverse effects)</term><term>Time Factors (MeSH)</term><term>Treatment Outcome (MeSH)</term><term>United Kingdom (MeSH)</term><term>Urinary Bladder, Overactive (diagnosis)</term><term>Urinary Bladder, Overactive (drug therapy)</term><term>Urinary Bladder, Overactive (physiopathology)</term><term>Urological Agents (administration & dosage)</term><term>Urological Agents (adverse effects)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Acetanilides</term><term>Adrenergic beta-3 Receptor Agonists</term><term>Muscarinic Antagonists</term><term>Thiazoles</term><term>Urological Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Acetanilides</term><term>Adrenergic beta-3 Receptor Agonists</term><term>Muscarinic Antagonists</term><term>Thiazoles</term><term>Urological Agents</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Urinary Bladder, Overactive</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Urinary Bladder, Overactive</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Urinary Bladder, Overactive</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Chi-Square Distribution</term><term>Databases, Factual</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Logistic Models</term><term>Longitudinal Studies</term><term>Male</term><term>Medication Adherence</term><term>Middle Aged</term><term>Odds Ratio</term><term>Proportional Hazards Models</term><term>Retrospective Studies</term><term>Time Factors</term><term>Treatment Outcome</term><term>United Kingdom</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Persistence with antimuscarinic therapy in overactive bladder (OAB) is poor, but may be different for mirabegron, a β</p></div><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>To compare persistence and adherence with mirabegron versus tolterodine extended release (ER) and other antimuscarinics in routine clinical practice over a 12-mo period.</p></div><div type="abstract" xml:lang="en"><p><b>DESIGN, SETTING, AND PARTICIPANTS</b></p><p>Retrospective, longitudinal, observational study of anonymised data from the UK Clinical Practice Research Datalink GOLD database. Eligibility: age ≥18 yr, ≥1 prescription for target OAB drug (between May 1, 2013 and June 29, 2014), and 12-mo continuous enrolment before and after the index prescription date.</p></div><div type="abstract" xml:lang="en"><p><b>INTERVENTIONS</b></p><p>Mirabegron, darifenacin, fesoterodine, flavoxate, oxybutynin ER or immediate-release (IR), propiverine, solifenacin, tolterodine ER or IR, and trospium chloride.</p></div><div type="abstract" xml:lang="en"><p><b>OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS</b></p><p>The primary endpoint was persistence (time to discontinuation). Secondary endpoints included 12-mo persistence rates and adherence (assessed using medication possession ratio, MPR). Cox proportional-hazards regression models and logistic regression models adjusted for potential confounding factors were used to compare cohorts. Analyses were repeated after 1:1 matching.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS AND LIMITATIONS</b></p><p>The study population included 21996 eligible patients. In the unmatched analysis, the median time-to-discontinuation was significantly longer for mirabegron (169 d, interquartile range [IQR] 41-not reached) compared to tolterodine ER (56 d, IQR 28-254; adjusted hazard ratio [HR] 1.55, 95% confidence interval 1.41-1.71; p<0.0001) and other antimuscarinics (range 30-78 d; adjusted HR range 1.24-2.26, p<0.0001 for all comparisons). The 12-mo persistence rates and MPR were also significantly greater with mirabegron than with all the antimuscarinics. Limitations include the retrospective design, use of prescription records to estimate outcomes, and inability to capture reasons for discontinuation.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Persistence and adherence were statistically significantly greater with mirabegron than with tolterodine ER and other antimuscarinics prescribed for OAB in the UK.</p></div><div type="abstract" xml:lang="en"><p><b>PATIENT SUMMARY</b></p><p>This study assessed persistence and adherence (or compliance) with medications prescribed for OAB in a large UK population. We found that patients prescribed mirabegron remained on treatment for longer and showed greater adherence than those prescribed traditional antimuscarinics.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28196724</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>08</Day></DateCompleted><DateRevised><Year>2018</Year><Month>05</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7560</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>09</Month></PubDate></JournalIssue><Title>European urology</Title><ISOAbbreviation>Eur Urol</ISOAbbreviation></Journal><ArticleTitle>Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.</ArticleTitle><Pagination><MedlinePgn>389-399</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0302-2838(17)30062-3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eururo.2017.01.037</ELocationID><Abstract><AbstractText Label="BACKGROUND">Persistence with antimuscarinic therapy in overactive bladder (OAB) is poor, but may be different for mirabegron, a β<sub>3</sub>-adrenoceptor agonist with a different adverse event profile.</AbstractText><AbstractText Label="OBJECTIVE">To compare persistence and adherence with mirabegron versus tolterodine extended release (ER) and other antimuscarinics in routine clinical practice over a 12-mo period.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">Retrospective, longitudinal, observational study of anonymised data from the UK Clinical Practice Research Datalink GOLD database. Eligibility: age ≥18 yr, ≥1 prescription for target OAB drug (between May 1, 2013 and June 29, 2014), and 12-mo continuous enrolment before and after the index prescription date.</AbstractText><AbstractText Label="INTERVENTIONS">Mirabegron, darifenacin, fesoterodine, flavoxate, oxybutynin ER or immediate-release (IR), propiverine, solifenacin, tolterodine ER or IR, and trospium chloride.</AbstractText><AbstractText Label="OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS">The primary endpoint was persistence (time to discontinuation). Secondary endpoints included 12-mo persistence rates and adherence (assessed using medication possession ratio, MPR). Cox proportional-hazards regression models and logistic regression models adjusted for potential confounding factors were used to compare cohorts. Analyses were repeated after 1:1 matching.</AbstractText><AbstractText Label="RESULTS AND LIMITATIONS">The study population included 21996 eligible patients. In the unmatched analysis, the median time-to-discontinuation was significantly longer for mirabegron (169 d, interquartile range [IQR] 41-not reached) compared to tolterodine ER (56 d, IQR 28-254; adjusted hazard ratio [HR] 1.55, 95% confidence interval 1.41-1.71; p<0.0001) and other antimuscarinics (range 30-78 d; adjusted HR range 1.24-2.26, p<0.0001 for all comparisons). The 12-mo persistence rates and MPR were also significantly greater with mirabegron than with all the antimuscarinics. Limitations include the retrospective design, use of prescription records to estimate outcomes, and inability to capture reasons for discontinuation.</AbstractText><AbstractText Label="CONCLUSIONS">Persistence and adherence were statistically significantly greater with mirabegron than with tolterodine ER and other antimuscarinics prescribed for OAB in the UK.</AbstractText><AbstractText Label="PATIENT SUMMARY">This study assessed persistence and adherence (or compliance) with medications prescribed for OAB in a large UK population. We found that patients prescribed mirabegron remained on treatment for longer and showed greater adherence than those prescribed traditional antimuscarinics.</AbstractText><CopyrightInformation>Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chapple</LastName><ForeName>Christopher R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Department of Urology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals, Sheffield, UK. Electronic address: c.r.chapple@sheffield.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nazir</LastName><ForeName>Jameel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Astellas Pharma Europe Ltd., Astellas Medical Affairs, EMEA, HEOR, Chertsey, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hakimi</LastName><ForeName>Zalmai</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Astellas Pharma Europe B.V., Astellas Medical Affairs, Global, HEOR, Leiden, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowditch</LastName><ForeName>Sally</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Astellas Pharma Europe Ltd., Astellas Medical Affairs, EMEA, HEOR, Chertsey, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fatoye</LastName><ForeName>Francis</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Health Professions, Manchester Metropolitan University, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guelfucci</LastName><ForeName>Florent</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Creativ-Ceutical, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khemiri</LastName><ForeName>Amine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Creativ-Ceutical SARL, Les Berges du lac, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siddiqui</LastName><ForeName>Emad</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Astellas Pharma Europe Ltd., Astellas Medical Affairs, EMEA, HEOR, Chertsey, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagg</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>02</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Eur Urol</MedlineTA><NlmUniqueID>7512719</NlmUniqueID><ISSNLinking>0302-2838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000083">Acetanilides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058667">Adrenergic beta-3 Receptor Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018727">Muscarinic Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064804">Urological Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>MVR3JL3B2V</RegistryNumber><NameOfSubstance UI="C520025">mirabegron</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Eur Urol. 2017 Sep;72 (3):400-401</RefSource><PMID Version="1">28400166</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Transl Androl Urol. 2017 Jun;6(3):597-601</RefSource><PMID Version="1">28725606</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Transl Androl Urol. 2017 Jun;6(3):602-603</RefSource><PMID Version="1">28725607</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000083" MajorTopicYN="N">Acetanilides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058667" MajorTopicYN="N">Adrenergic beta-3 Receptor Agonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055118" MajorTopicYN="Y">Medication Adherence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018727" MajorTopicYN="N">Muscarinic Antagonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N">United Kingdom</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053201" MajorTopicYN="N">Urinary Bladder, Overactive</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064804" MajorTopicYN="N">Urological Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Adherence</Keyword><Keyword MajorTopicYN="Y">Antimuscarinics</Keyword><Keyword MajorTopicYN="Y">Mirabegron</Keyword><Keyword MajorTopicYN="Y">Observational</Keyword><Keyword MajorTopicYN="Y">Overactive bladder</Keyword><Keyword MajorTopicYN="Y">Persistence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>01</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28196724</ArticleId><ArticleId IdType="pii">S0302-2838(17)30062-3</ArticleId><ArticleId IdType="doi">10.1016/j.eururo.2017.01.037</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/MaghrebDataLibMedV2/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000450 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000450 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= MaghrebDataLibMedV2
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28196724
|texte= Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28196724" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MaghrebDataLibMedV2
| This area was generated with Dilib version V0.6.38. |  |